ClinicalTrials.gg
CompletedNCT01798056Updated May 13, 2021Results posted

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

A Phase 3 interventional study of GSK 1437173A and Placebo in Herpes Zoster and Herpes Zoster Vaccine, sponsored by GlaxoSmithKline. Completed at 28 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
24th of 46
237 · median 239
Started
2013
with 3 others
Phase 3
22 of 46
2 open now
Registered
10th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 24th largest by enrollment, is one of 4 that started in 2013, is one of 22 in phase 3, and was the 10th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults with solid tumours undergoing chemotherapy.

Read the detailed description

The study will be randomised into two groups based on the vaccination schedule in relation to the start of a chemotherapy cycle:

  • The OnChemo group receives their first HZ/su vaccination at the start of a chemotherapy cycle,
  • The PreChemo group receives their first HZ/su vaccination at least 10 days before the start of a chemotherapy cycle.

The protocol summary has been updated following Protocol Amendment 2, August 2014, leading to the increase of the enrolment.

03

Conditions studied

  • Herpes Zoster
  • Herpes Zoster Vaccine

Browse trials for

Keywords

  • ≥18 years of age
  • Chemotherapy
  • Solid tumours
  • Immunogenicity
  • Herpes Zoster
  • Safety
  • Shingles
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written obtained from the subject.
  • A male or female aged 18 years or older (and has reached the age of legal consent) at the time of study entry (i.e., when informed consent is signed).
  • Subject who has been diagnosed with one or more solid tumours (defined as a solid , i.e., not a blood element malignancy).
  • Subject who is receiving or will receive a cytotoxic or chemotherapy (such that the study vaccine can be administered at the latest at the start of the second cycle of chemotherapy).
  • of greater than one year.
  • Female subjects of non- may be enrolled in the study:

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or ;
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Subjects receiving only newer, more targeted therapies if not taken together with a classical chemotherapy.
  • Chronic administration and/or planned administration of systemic within one month prior to the first vaccine dose and up to Visit 3 (Month 2). Inhaled, intra-articularly injected, and topical steroids are allowed.
  • Previous vaccination against HZ or varicella within 12 months preceding the first dose of study vaccine/ placebo.
  • Planned administration during the study of a HZ vaccine (including an or non-registered vaccine) other than the study vaccine.
  • Previous chemotherapy course less than one month before first study vaccination.
  • Occurrence of a varicella or HZ episode by clinical history within the 12 months preceding the first dose of study vaccine/ placebo.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine or study material and equipment.
  • Administration or planned administration of a in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.
  • infection by clinical history.
  • Acute disease and/or fever at the time of vaccination. Acute disease is defined as the presence of a moderate or severe illness with or without fever, but excludes the underlying , as well as the expected symptoms/signs associated with that disease or its treatment:

    • Fever is defined as temperature ≥ 37.5°C /99.5°F on oral, axillary or tympanic setting, or ≥ 38.0°C /100.4°F on rectal setting. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever, may receive the first dose of study vaccine/ placebo at the discretion of the investigator.
  • Any condition which, in the judgment of the investigator would make intramuscular injection unsafe.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions (if of ) before Month 3 (i.e., 2 months after the last dose of study vaccine/ placebo).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
237 participants (actual)

Study arms

  • Experimental
    GSK1437173A Group

    Subjects received the first dose of GSK 1437173A at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of GSK 1437173A vaccine was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.

    Biological: GSK 1437173A

  • Placebo comparator
    Placebo Group

    Subjects received the first dose of placebo at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of placebo was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.

    Drug: Placebo

Interventions

  • BiologicalGSK 1437173A

    2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.

    Also known as: HZ/su, GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine

  • DrugPlacebo

    2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.

06

What researchers measure

Primary outcomes

  1. Adjusted Geometric Means for Anti-glycoprotein E (gE) Antibodies in PreChemo Groups

    Adjusted geometric means (GMC) of GSK1437173A over placebo for anti-glycoprotein E (gE) antibody enzyme-linked immunosorbent assay (ELISA) concentrations in PreChemo Groups only.

    Time frame: At Month 2

  2. Anti-Varicella Zoster Virus (VZV) gE Antibody Concentrations

    Antibody concentrations as determined by ELISA are presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU//mL.

    Time frame: At Month 2

  3. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal every day activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  4. Number of Days With Solicited Local Symptoms

    The number of days with any local symptoms has been assessed during the post-vaccination period.

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose

  5. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal \[symptoms included nausea, vomiting, diarrhoea and/or abdominal pain\], headache, myalgia, shivering and fever \[defined as oral, axillary or tympanic temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  6. Number of Days With Solicited General Symptoms

    The number of days with any general symptoms has been assessed during the post-vaccination period.

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose

  7. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: During the 30-day (Days 0-29) post-vaccination period

  8. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE= SAE assessed by the investigator as causally related to the study vaccination.

    Time frame: From first dose up to 30 days post last vaccination

  9. Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMDs assessed by the investigator as causally related to the study vaccination.

    Time frame: From first vaccination up to 30 days post last vaccination

Secondary outcomes

  1. Anti-VZV gE Antibody Concentrations

    Antibody concentrations as determined by ELISA are presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU//mL.

    Time frame: At Months 0, 1, 6 and 13

  2. Number of Subjects With Vaccine Responses for Anti-gE Antibody ELISA Concentrations

    Vaccine response defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/ml); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

    Time frame: At Months 1, 2, 6 and 13

  3. Descriptive Statistics of the Frequency of gE-specific CD4[2+] T-cells in PreChemo Groups

    Descriptive statistics were tabulated for CD4\[2+\] cells, which are gE specific CD4+ T-cells with at least two activation markers (\[2+\]), expressed from the activation markers interferon-gamma (IFN-γ), interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40-ligand (CD40-L), as determined by intracellular cytokine staining (ICS) method.

    Time frame: At Months 0, 1, 2 and 13

  4. Number of Subjects With Vaccine Responses for gE-specific CD4[2+] T-cells in PreChemo Groups

    Vaccine response defined as: For initially seronegative subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x320 Events/10E6 CD4+ T cells); For initially seropositive subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.

    Time frame: At Months 1, 2 and 13

  5. Number of Subjects With Serious Adverse Events (SAEs)

    SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE = SAE assessed by the investigator as causally related to the study vaccination.

    Time frame: From 30 days post last vaccination up to study end (Month 13)

  6. Number of Subjects With Any Potential Immune Mediated Diseases (pIMDs)

    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From 30 days post last vaccination up to study end (Month 13)

07

Results

Posted Aug 17, 2018

Participant flow

Participant flow — Overall Study
MilestoneGSK1437173A GroupPlacebo Group
Started117115
Completed9090
Not completed2725
Withdrew: Serious adverse event1312
Withdrew: Withdrawal by subject129
Withdrew: Migrated/moved from study area11
Withdrew: Lost to follow-up11
Withdrew: Other02

Outcome measures

PrimaryAdjusted Geometric Means for Anti-glycoprotein E (gE) Antibodies in PreChemo Groups

Adjusted geometric means (GMC) of GSK1437173A over placebo for anti-glycoprotein E (gE) antibody enzyme-linked immunosorbent assay (ELISA) concentrations in PreChemo Groups only.

Time frame:
At Month 2
Reported as:
Geometric mean · EL.U/mL
Adjusted Geometric Means for Anti-glycoprotein E (gE) Antibodies in PreChemo Groups
EL.U/mLGSK1437173A-PreChemoPlaceb-PreChemo
Adjusted Geometric Means for Anti-glycoprotein E (gE) Antibodies in PreChemo Groups24501.57 (19051.99 to 31509.94)1056.77 (990.37 to 1127.62)
Statistical analysis
  • GSK1437173A-PreChemo vs Placeb-PreChemo · Adjusted gmc ratio: 23.2 · 95% CI 17.9 to 30Difference of means between vaccines and placebo were calculated together with 2-sided confidence intervals and back-transformed to the original units
PrimaryAnti-Varicella Zoster Virus (VZV) gE Antibody Concentrations

Antibody concentrations as determined by ELISA are presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU//mL.

Time frame:
At Month 2
Reported as:
Geometric mean · mIU/mL
Anti-Varicella Zoster Virus (VZV) gE Antibody Concentrations
mIU/mLGSK1437173A GroupPlacebo Group
Anti-Varicella Zoster Virus (VZV) gE Antibody Concentrations18291.7 (14432.1 to 23183.5)1060.5 (873.9 to 1287.1)
PrimaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal every day activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsGSK1437173A GroupPlacebo Group
Any Pain, Dose 1832
Grade 3 Pain, Dose 180
Any Redness, Dose 1330
Grade 3 Redness, Dose 120
Any Swelling, Dose 1151
Grade 3 Swelling, Dose 100
Any Pain, Dose 2525
Grade 3 Pain, Dose 240
Any Redness, Dose 2200
Grade 3 Redness, Dose 200
Any Swelling, Dose 280
Grade 3 Swelling, Dose 200
Any Pain, Across doses907
Grade 3 Pain, Across doses110
Any Redness, Across doses400
Grade 3 Redness, Across doses20
Any Swelling, Across doses181
Grade 3 Swelling, Across doses00
PrimaryNumber of Days With Solicited Local Symptoms

The number of days with any local symptoms has been assessed during the post-vaccination period.

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose
Reported as:
Median · Days
Number of Days With Solicited Local Symptoms
DaysGSK1437173A GroupPlacebo Group
Pain, Dose 12.0 (2.0 to 4.0)2.0 (1.0 to 3.0)
Pain, Dose 22.0 (1.0 to 3.5)1.0 (1.0 to 2.0)
Redness, Dose 13.0 (2.0 to 5.0)—
Redness, Dose 24.0 (2.0 to 5.0)—
Swelling, Dose 14.0 (2.0 to 5.0)7.0 (7.0 to 7.0)
Swelling, Dose 23.5 (2 to 5.5)—
PrimaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal \[symptoms included nausea, vomiting, diarrhoea and/or abdominal pain\], headache, myalgia, shivering and fever \[defined as oral, axillary or tympanic temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsGSK1437173A GroupPlacebo Group
Any Fatigue, Dose 15644
Grade 3 Fatigue, Dose 1103
Related Fatigue, Dose 11510
Any Gastrointestinal, Dose 13221
Grade 3 Gastrointestinal, Dose 125
Related Gastrointestinal, Dose 192
Any Headache, Dose 12824
Grade 3 Headache, Dose 131
Related Headache, Dose 1104
Any Myalgia, Dose 15017
Grade 3 Myalgia, Dose 183
Related Myalgia, Dose 1253
Any Shivering, Dose 12713
Grade 3 Shivering, Dose 152
Related Shivering, Dose 1124
Any Fever, Dose 1134
Grade 3 Fever, Dose 100
Related Fever, Dose 1111
Any Fatigue, Dose 25757
Grade 3 Fatigue, Dose 296
Related Fatigue, Dose 268
Any Gastrointestinal, Dose 24139
Grade 3 Gastrointestinal, Dose 253
Related Gastrointestinal, Dose 262
Any Headache, Dose 22925
Grade 3 Headache, Dose 232
Related Headache, Dose 272
Any Myalgia, Dose 23223
Grade 3 Myalgia, Dose 241
Related Myalgia, Dose 2134
Any Shivering, Dose 22017
Grade 3 Shivering, Dose 231
Related Shivering, Dose 264
Any Fever, Dose 281
Grade 3 Fever, Dose 200
Related Fever, Dose 240
Any Fatigue, Across doses7868
Grade 3 Fatigue, Across doses168
Related Fatigue, Across doses1914
Any Gastrointestinal, Across doses5149
Grade 3 Gastrointestinal, Across doses67
Related Gastrointestinal, Across doses113
Any Headache, Across doses4340
Grade 3 Headache, Across doses63
Related Headache, Across doses166
Any Myalgia, Across doses6031
Grade 3 Myalgia, Across doses124
Related Myalgia, Across doses305
Any Shivering, Across doses3925
Grade 3 Shivering, Across doses63
Related Shivering, Across doses165
Any Temperature, Across doses205
Grade 3 Temperature, Across doses00
Related Temperature, Across doses141
PrimaryNumber of Days With Solicited General Symptoms

The number of days with any general symptoms has been assessed during the post-vaccination period.

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose
Reported as:
Median · Days
Number of Days With Solicited General Symptoms
DaysGSK1437173A GroupPlacebo Group
Fatigue, Dose 13.0 (1.5 to 6.0)5.0 (2.0 to 6.0)
Fatigue, Dose 25.0 (2.0 to 7.0)5.0 (3.0 to 7.0)
Gastrointestinal symptoms, Dose 12.5 (1.5 to 4.0)4.0 (2.0 to 6.0)
Gastrointestinal symptoms, Dose 24.0 (3.0 to 7.0)3.0 (2.0 to 7.0)
Headache, Dose 12.0 (1.0 to 3.5)2.0 (1.5 to 4.5)
Headache, Dose 22.0 (2.0 to 6.0)2.0 (1.0 to 5.0)
Myalgia, Dose 12.5 (1.0 to 4.0)2.0 (2.0 to 6.0)
Myalgia, Dose 23.0 (2.0 to 5.5)5.0 (3.0 to 7.0)
Shivering, Dose 12.0 (1.0 to 3.0)2.0 (1.0 to 2.0)
Shivering, Dose 23.0 (1.0 to 6.0)2.0 (1.0 to 4.0)
Temperature, Dose 11.0 (1.0 to 2.0)1.0 (1.0 to 3.0)
Temperature, Dose 21.5 (1.0 to 2.5)1.0 (1.0 to 1.0)
PrimaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
During the 30-day (Days 0-29) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
ParticipantsGSK1437173A GroupPlacebo Group
Any AE(s)100103
Grade 3 AE(s)1815
Related AE(s)109
PrimaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE= SAE assessed by the investigator as causally related to the study vaccination.

Time frame:
From first dose up to 30 days post last vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsGSK1437173A GroupPlacebo Group
Any SAEs1614
Related SAEs00
PrimaryNumber of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMDs assessed by the investigator as causally related to the study vaccination.

Time frame:
From first vaccination up to 30 days post last vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
ParticipantsGSK1437173A GroupPlacebo Group
Any pIMDs00
Related pIMDs00
SecondaryAnti-VZV gE Antibody Concentrations

Antibody concentrations as determined by ELISA are presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU//mL.

Time frame:
At Months 0, 1, 6 and 13
Reported as:
Geometric mean · mIU/mL
Anti-VZV gE Antibody Concentrations
mIU/mLGSK1437173A GroupPlacebo Group
Anti-VZV gE, Month 01049.8 (865.8 to 1273.0)1116.7 (918.4 to 1358.0)
Anti-VZV gE, Month 124793.1 (18747.8 to 32787.6)1107.2 (920.0 to 1332.6)
Anti-VZV gE, Month 67730.4 (5358.4 to 11152.2)1380.2 (1066.3 to 1786.6)
Anti-VZV gE, Month 134477.3 (3482.4 to 5756.3)1064.7 (845.9 to 1340.1)
SecondaryNumber of Subjects With Vaccine Responses for Anti-gE Antibody ELISA Concentrations

Vaccine response defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/ml); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

Time frame:
At Months 1, 2, 6 and 13
Reported as:
Count of participants · Participants
Number of Subjects With Vaccine Responses for Anti-gE Antibody ELISA Concentrations
ParticipantsGSK1437173A GroupPlacebo Group
Vaccine responders Month 1730
Vaccine responders Month 2750
Vaccine responders Month 6311
Vaccine responders Month 13350
SecondaryDescriptive Statistics of the Frequency of gE-specific CD4[2+] T-cells in PreChemo Groups

Descriptive statistics were tabulated for CD4\[2+\] cells, which are gE specific CD4+ T-cells with at least two activation markers (\[2+\]), expressed from the activation markers interferon-gamma (IFN-γ), interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40-ligand (CD40-L), as determined by intracellular cytokine staining (ICS) method.

Time frame:
At Months 0, 1, 2 and 13
Reported as:
Median · CD4 T-cells/million T-cells
Descriptive Statistics of the Frequency of gE-specific CD4[2+] T-cells in PreChemo Groups
CD4 T-cells/million T-cellsGSK1437173A-PreChemoPlaceb-PreChemo
CD4[2+] T-cells, Month 0127.3 (49.7 to 192.4)104.8 (27.5 to 151.5)
CD4[2+] T-cells, Month 1391.9 (139.7 to 603.7)50.0 (1.0 to 179.4)
CD4[2+] T-cells, Month 2778.8 (393.1 to 1098.2)61.8 (17.4 to 139.5)
CD4[2+] T-cells, Month 13332.9 (114.9 to 604.6)51.2 (1.0 to 288.6)
SecondaryNumber of Subjects With Vaccine Responses for gE-specific CD4[2+] T-cells in PreChemo Groups

Vaccine response defined as: For initially seronegative subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x320 Events/10E6 CD4+ T cells); For initially seropositive subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.

Time frame:
At Months 1, 2 and 13
Reported as:
Count of participants · Participants
Number of Subjects With Vaccine Responses for gE-specific CD4[2+] T-cells in PreChemo Groups
ParticipantsGSK1437173A-PreChemoPlaceb-PreChemo
CD4[2+] T-cells, Month 150
CD4[2+] T-cells, Month 2110
CD4[2+] T-cells, Month 1330
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE = SAE assessed by the investigator as causally related to the study vaccination.

Time frame:
From 30 days post last vaccination up to study end (Month 13)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsGSK1437173A GroupPlacebo Group
Any SAEs3031
Related SAEs00
SecondaryNumber of Subjects With Any Potential Immune Mediated Diseases (pIMDs)

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From 30 days post last vaccination up to study end (Month 13)
Reported as:
Count of participants · Participants
Number of Subjects With Any Potential Immune Mediated Diseases (pIMDs)
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With Any Potential Immune Mediated Diseases (pIMDs)01

Adverse events

Collected over Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-vaccination period; SAEs: from first dose up to study end (Month 13).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A Group12/117 (10.3%)36/117 (30.8%)113/117 (96.6%)
Placebo Group11/115 (9.6%)42/115 (36.5%)103/115 (89.6%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventGSK1437173A GroupPlacebo Group
Febrile neutropeniaBlood and lymphatic system disorders6/1172/115
NeutropeniaBlood and lymphatic system disorders2/1174/115
AnaemiaBlood and lymphatic system disorders2/1173/115
SepsisInfections and infestations3/1172/115
ThrombocytopeniaBlood and lymphatic system disorders0/1172/115
ConstipationGastrointestinal disorders0/1172/115
Neutropenic sepsisInfections and infestations1/1172/115
PneumoniaInfections and infestations1/1172/115
Acute kidney injuryRenal and urinary disorders1/1172/115
Pleural effusionRespiratory, thoracic and mediastinal disorders1/1172/115
Most frequent other events
Showing 10 of 20
Most frequent other events
EventGSK1437173A GroupPlacebo Group
PainGeneral disorders90/1177/115
FatigueGeneral disorders80/11769/115
MyalgiaMusculoskeletal and connective tissue disorders62/11733/115
Gastrointestinal disorderGastrointestinal disorders51/11751/115
HeadacheNervous system disorders45/11741/115
ErythemaSkin and subcutaneous tissue disorders43/1171/115
ChillsGeneral disorders39/11725/115
NauseaGastrointestinal disorders31/11728/115
AstheniaGeneral disorders30/11728/115
AlopeciaSkin and subcutaneous tissue disorders21/11723/115

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A GroupPlacebo GroupTotal
Mean57.1 ± 10.858.5 ± 11.757.79 ± 11.25
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A GroupPlacebo GroupTotal
Female7069139
Male474693
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK1437173A GroupPlacebo GroupTotal
Geographic ancestry — African Heritage/African American224
Geographic ancestry — American Indian or Alaskan Native202
Geographic ancestry — Asian - East Asian Heritage111425
Geographic ancestry — Asian - South East Asian Heritage022
Geographic ancestry — White - Arabic/North African Heritage101
Geographic ancestry — White - Caucasian/European Heritage9288180
Geographic ancestry — Mixed Origin011
Geographic ancestry — Missing9817
08

Study locations

28 sites
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 6R8, Canada
  • GSK Investigational Site
    Toronto, Ontario M4C 3E7, Canada
  • GSK Investigational Site
    Montreal, Quebec H4J 1C5, Canada
  • GSK Investigational Site
    Praha 8, 180 00, Czechia
  • GSK Investigational Site
    Besançon cedex, 25030, France
  • GSK Investigational Site
    Ferolles-Attilly, 77150, France
  • GSK Investigational Site
    Lyon Cedex 08, 69373, France
  • GSK Investigational Site
    Nîmes cedex 9, 30029, France
  • GSK Investigational Site
    Seoul, 02841, Korea, Republic of
  • GSK Investigational Site
    Seoul, 03080, Korea, Republic of
  • GSK Investigational Site
    Seoul, 05505, Korea, Republic of
  • GSK Investigational Site
    Badajoz, 6080, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28050, Spain
  • GSK Investigational Site
    Majadahonda (Madrid), 28222, Spain
  • GSK Investigational Site
    Móstoles, 28935, Spain
  • GSK Investigational Site
    Pozuelo De Alarcón/Madrid, 28223, Spain
  • GSK Investigational Site
    San Sebastian de los Reyes, 28702, Spain
  • GSK Investigational Site
    Cheltenham, Gloucestershire GL53 7AN, United Kingdom
  • GSK Investigational Site
    Woolwich, London SE18 4QH, United Kingdom
  • GSK Investigational Site
    Swindon, Wiltshire SN3 6BB, United Kingdom
  • GSK Investigational Site
    Exeter, EX2 5DW, United Kingdom
  • GSK Investigational Site
    Sheffield, S10 2SJ, United Kingdom
  • GSK Investigational Site
    York, YO31 8HE, United Kingdom
09

References and documents

Publications

  • Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, Kristeleit H, Farrugia D, McNeil SA, Campora L, Di Paolo E, El Idrissi M, Godeaux O, Lopez-Fauqued M, Salaun B, Heineman TC, Oostvogels L; Zoster-028 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. Cancer. 2019 Apr 15;125(8):1301-1312. doi: 10.1002/cncr.31909. Epub 2019 Feb 1. Erratum In: Cancer. 2020 Jun 15;126(12):2941. doi: 10.1002/cncr.32842. PubMed 30707761 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Jun 2015, 27 months.

Results were first posted in Aug 2018, 3 years 1 month after primary completion. A results delay was requested in Nov 2015.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 27 months is above that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2013
First posted
Feb 25, 2013
StartActual
Mar 6, 2013
Primary completionActual
Jun 18, 2015
CompletionActual
May 20, 2016
Results delay requested
Nov 12, 2015
Results first posted
Aug 17, 2018
Last update
May 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01798056
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 25, 2013
Start date
Mar 6, 2013
Primary completion
Jun 18, 2015
Completion
May 20, 2016
Results posted
Aug 17, 2018
Last update
May 13, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion